Recursion Pharmaceuticals, Inc. (RXRX)
| Market Cap | 1.92B |
| Revenue (ttm) | 46.24M |
| Net Income (ttm) | -354.11M |
| Shares Out | 268.29M |
| EPS (ttm) | -1.62 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,966,435 |
| Open | 7.43 |
| Previous Close | 7.46 |
| Day's Range | 7.04 - 7.44 |
| 52-Week Range | 4.97 - 16.75 |
| Beta | 0.86 |
| Analysts | Buy |
| Price Target | 17.40 (+143.02%) |
| Earnings Date | Aug 6, 2024 |
About RXRX
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; R... [Read more]
Financial Performance
In 2023, RXRX's revenue was $44.58 million, an increase of 11.88% compared to the previous year's $39.84 million. Losses were -$328.07 million, 37.0% more than in 2022.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for RXRX stock is "Buy." The 12-month stock price forecast is $17.4, which is an increase of 143.02% from the latest price.
News
Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock
Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discover...
Recursion Announces Proposed Offering of Class A Common Stock
Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discover...
Recursion CEO Chris Gibson talks integrating AI into drug development process
Chris Gibson, Recursion Pharmaceuticals CEO, joins 'Closing Bell Overtime' to talk its partnership with Nvidia, its investors day, drug discovery and more.
Helix and Recursion Pharmaceuticals Drive Drug Discovery Innovation Through Clinico-Genomic Data
SAN MATEO, Calif.--(BUSINESS WIRE)--Helix, a leading population genomics company and provider of precision medicine genomics solutions, today announced a groundbreaking multi-year agreement with Recur...
Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day
SALT LAKE CITY, June 24, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will give updated pipeline guidan...
Nvidia Owns These 4 Stocks. Here's How They're Doing.
Nvidia has been one of the best-performing stocks on Wall Street since 2023, amassing holdings in four companies along the way.
Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool
Published open-access today in Nature Genetics, “High-resolution genome-wide mapping of chromosome-arm-scale truncations induced by CRISPR–Cas9 editing” identifies novel evidence of a proximity bias i...
Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board
Dr. Hershberg is a current board member with over 25 years of experience as a physician, scientist, and entrepreneur Dr. Hershberg is a current board member with over 25 years of experience as a physi...
Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry
BioHive-2, an NVIDIA DGX SuperPOD with NVIDIA DGX H100 systems, ranked #35 in the TOP500 list of the most powerful supercomputers in the world across all industries as of May 2024. BioHive-2, an NVIDI...
Recursion Pharmaceuticals CEO Chris Gibson goes one-on-one with Jim Cramer
Recursion Pharmaceuticals Co-Founder and CEO Chris Gibson joins 'Mad Money' host Jim Cramer to talk integrating machine learnings into drug development and partnering with Nvidia.
We've built an unbiased platform that lets data drive decisions, not us, says Recursion CEO
Recursion Pharmaceuticals Co-Founder and CEO Chris Gibson joins 'Mad Money' host Jim Cramer to talk integrating machine learnings into drug development and partnering with Nvidia.
Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results
SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates an...
Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9
SALT LAKE CITY, May 02, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide bu...
Recursion to Participate in Upcoming Investor Conferences
SALT LAKE CITY, May 01, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation ...
Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX
Biotech stocks are having a relatively strong year as investors focus on the growing M&A in the healthcare space. Johnson & Johnson is acquiring Shockwave Medical while Novo Nordisk is buying Catalent...
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion's Board of Directors Dr. Khan,...
Recursion Publishes Annual Environmental, Social and Governance Report
Provides progress updates in support of long-term commitments focused on reducing greenhouse gas emissions, improving workforce diversity and accelerating community impact. Provides progress updates i...
Not just Soundhound, these AI stocks are also riding Nvidia wave
Following Nvidia's investment disclosure, SoundHound AI's shares have dramatically increased, tripling in value and boosting its market capitalization to $2.75 billion. The company's success is attrib...
Recursion Announces Plans to Open New Office in London
Appoints Michael Bronstein as Scientific Advisor and launches recruiting effort to fill the first 20 open roles across technology and biology, establishing a hub for world-class TechBio talent in the ...
Recursion Hosts Second Annual Rare Disease Day Events for Utah's Rare Disease Community
SALT LAKE CITY, March 01, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, hosted its second annual Rare Di...
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results
SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates a...
Recursion to Host Public L(earnings) Call on February 27
SALT LAKE CITY, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide b...
Nvidia discloses investments in smaller AI firms
Nvidia (NVDA) has disclosed investments made in several emerging AI companies, sparking rallies across these stocks. Among the names benefiting include Soundhound (SOUN), Arm (ARM), and Nanox (NNOX).
Shares of Smaller AI Firms Rise After Nvidia Discloses Investments
Shares of smaller artificial intelligence (AI) firms reportedly experienced a rally Thursday (Feb. 15) after Nvidia, the world's leading AI chipmaker, disclosed its stake in them as of Dec. 31. This m...
Altitude Lab Startups Raise Over $120M in Capital
SALT LAKE CITY, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Altitude Lab today announced that its incubating startups raised over $120M in early-stage funding since commencing operations in 2020. Altitude Lab w...